



Supplementary Material


1 Supplementary Figures



Supplementary Figure 1. The cellular viability of LX-2 (A) and HSC-T6 (B) cells treated with different concentrations of Schizandrin C, $n=3$. Data are expressed as Mean $\pm$ S.D.



Supplementary Figure 2. Permutation test of OPLS-DA. Permutation plots for model vs. control in positive (A) and negative (B) ion modes. Permutation plots for Schizandrin C vs. model in positive (C) and negative (D) ion modes.



Supplementary Figure 3. S-plot analysis of OPLS-DA. S-plots of relative abundances for model vs. control in positive (A) and negative (B) ion modes. S-plots of relative abundances for Schizandrin C vs. model in positive (C) and negative (D) ion modes.

2 Supplementary Tables

Supplementary Table 1. Sequence of primers for quantitative real-time PCR analysis.

Name	Forward (5'-3')	Reverse (5'-3')
<i>α-SMA</i>	GTCCCAGACATCAGGGAGTAA	TCCGATACTTCAGCGTCAGGA
<i>Col1a1</i>	TAAGGGTCCCCAATGGTGAGA	GGGTCCCTCGACTCCTACAT
<i>Cd36</i>	ATGGGCTGTGATCGGAACTG	GTCTTCCCAATAAGCATGTCTCC
<i>Fasn</i>	GGAGGTGGTGATAGCCGGTAT	TGGGTAATCCATAGAGCCCAG

<i>Scd1</i>	TTCTTGCGATACACTCTGGTGC	CGGGATTGAATGTTCTTGTCGT
<i>Srebf1</i>	TGACCCGGCTATTCCGTGA	CTGGGCTGAGCAATACAGTTC
<i>Acaca</i>	ATGGGCGGAATGGTCTCTTTC	TGGGGACCTTGTCTTCATCAT
<i>Cpt1a</i>	CTCCGCCTGAGCCATGAAG	CACCAGTGATGATGCCATTCT
<i>Acox1</i>	TAACTTCCTCACTCGAAGCCA	AGTTCCATGACCCATCTCTGTC
<i>Lcad</i>	TCTTTTCCTCGGAGCATGACA	GACCTCTCTACTCACTTCTCCAG
<i>Lpl</i>	GGGAGTTTGGCTCCAGAGTTT	TGTGTCTTCAGGGGTCCTTAG
<i>Mgl</i>	ACCATGCTGTGATGCTCTCTG	CAAACGCCTCGGGGATAACC
<i>Mtp</i>	AGCCAGTGGGCATAGAAAATC	GGTCACTTTACAATCCCCAGAG
<i>Apob</i>	AAGCACCTCCGAAAGTACGTG	CTCCAGCTCTACCTTACAGTTGA
<i>Il-6</i>	CTCCCAACAGACCTGTCTATAC	CCATTGCACAACCTCTTTTCTCA
<i>Tgfb-1</i>	CTTGCCCTCTACAACCAACA	ACTTGCGACCCACGTAGTAGA
<i>Tnfa</i>	ATGTCTCAGCCTCTTCTCATTC	GCTTGTCACCTCGAATTTTGAGA
<i>Cox-2</i>	GGATCATCAACACTGCCTCA	ATGGTGGCTGTCTTGGTAGG
<i>Gapdh</i>	GGTTGTCTCCTGCGACTTCA	TGGTCCAGGGTTTCTTACTCC
<i>α-SMA(rat)</i>	CCAGGGAGTGATGGTTGGA	CCGTTAGCAAGGTCGGATG
<i>Col1a1(rat)</i>	TGTTGGTCCTGCTGGCAAGAATG	GTCACCTTGTTGCGCTGTCTCAC
<i>Il-6 (rat)</i>	ACTTCCAGCCAGTTGCCTTCTTG	TGGTCTGTTGTGGGTGGTATCCTC

<i>Gapdh</i> (rat)	GACATGCCGCCTGGAGAAAC	AGCCCAGGATGCCCTTTAGT
α -SMA (human)	GTGTTGCCCCTGAAGAGCAT	GCTGGGACATTGAAAGTCTCA
<i>COL1A1</i> (human)	GAGGGCCAAGACGAAGACATC	CAGATCACGTCATCGCACAAAC
<i>IL-6</i> (human)	ACTCACCTCTTCAGAACGAATTG	CCATCTTTGGAAGGTTCAAGTTG
<i>GAPDH</i> (human)	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG

Supplementary Table 2. The information of 36 identified lipids simultaneously in Model vs. Control groups and Schizandrin C vs. Model groups.

Lipidname	m/z	Rt (min)	Model vs. Control			Schizandrin C vs. Model		
			VIP	<i>p</i> value	FC	VIP	<i>p</i> value	FC
ACar 16:0	399.33	2.23	1.10	0.02	2.64	1.41	0.02	3.45
ACar 18:0	427.37	3.63	1.08	0.02	2.10	1.48	0.02	2.07
Cer-NP (t15:1/24:1)	681.58	13.40	1.30	0.00	3.25	1.30	0.03	2.40
Cer-NS (d18:1/18:1)	609.53	11.60	1.32	0.00	4.08	1.02	0.10	2.01
HexCer-NDS (d18:0/24:1)	811.69	14.17	1.05	0.02	3.00	1.13	0.09	2.71
HexCer-NS (d30:1/12:0)	857.70	14.17	1.05	0.02	4.04	1.15	0.08	2.66
OxPC (18:0-20:3+2O)	889.61	8.57	1.15	0.01	0.45	1.65	0.00	0.49
OxPE (16:0-22:6+4O)	827.50	7.48	1.26	0.00	2.23	1.92	0.00	0.32
PC (16:2/17:2)	739.52	7.48	1.14	0.01	0.67	1.66	0.00	0.47

PC (18:0e/21:0)	817.70	14.51	1.11	0.02	0.78	1.78	0.00	0.61
PC (19:0/22:5)	849.62	12.01	1.42	0.00	0.54	1.63	0.00	0.71
PC (19:1/20:5)	819.59	7.96	1.39	0.00	0.48	1.77	0.00	0.37
PC (20:1/22:4)	863.64	12.59	1.28	0.00	0.16	1.01	0.11	0.35
PE (18:0/18:1)	745.56	12.94	1.35	0.00	1.55	1.99	0.00	1.65
PE (18:0/20:1)	773.59	12.63	1.13	0.01	1.36	1.88	0.00	1.56
PE (18:2e/24:4)	805.60	13.02	1.32	0.00	2.05	1.21	0.08	2.07
PE (19:0/20:4)	781.56	12.30	1.47	0.00	0.31	1.66	0.00	0.54
PE (20:0/20:1)	801.63	13.62	1.42	0.00	0.50	1.81	0.00	1.48
PE (20:0/20:3)	797.60	13.48	1.28	0.00	0.56	1.79	0.00	1.67
PE (21:2/20:5)	803.54	12.29	1.43	0.00	0.34	1.72	0.00	0.50
PG (16:0/20:3)	772.53	10.15	1.22	0.00	1.39	1.84	0.00	2.03
PG (20:4/22:6)	842.51	8.33	1.35	0.00	2.70	1.56	0.01	2.08
PI (16:1/18:2)	832.51	8.94	1.08	0.01	0.24	1.09	0.16	2.03
SM (d14:0/29:0)	876.72	14.98	1.29	0.00	1.54	1.90	0.00	0.52
SM (d27:0/12:1)	772.64	13.11	1.46	0.00	0.40	1.74	0.00	0.63
SM (d28:1/12:0)	786.66	13.62	1.42	0.00	0.63	1.73	0.00	0.67
TAG (15:2-18:1-18:2)	855.72	15.66	1.14	0.01	1.57	1.67	0.00	1.50

Supplementary Material

TAG (16:0-18:0-22:6)	928.75	16.97	1.48	0.00	2.75	1.79	0.00	0.62
TAG (16:0-18:2-20:3)	902.73	16.68	1.28	0.00	0.70	1.87	0.00	0.48
TAG (16:0-18:2-22:5)	921.78	16.39	1.46	0.00	1.68	1.68	0.00	0.81
TAG (18:0-18:1-18:1)	903.82	17.41	1.17	0.01	1.28	1.84	0.00	1.45
TAG (18:0-18:2-22:6)	947.79	16.60	1.45	0.00	1.79	1.67	0.00	1.39
TAG (18:1-18:2-22:5)	952.75	16.37	1.36	0.00	2.03	1.72	0.00	0.64
TAG (18:1-19:1-20:3)	939.82	17.02	1.25	0.00	1.66	1.61	0.00	1.40
TAG (18:1-20:1-22:5)	977.84	16.99	1.52	0.00	2.50	1.59	0.00	1.45
TAG (18:1-22:4-22:6)	1002.76	16.37	1.38	0.00	1.93	1.70	0.00	0.55
